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Brief Definit ive Report
Hepatitis C virus (HCV) is a positive-strand 
RNA virus that belongs to the Flaviviridae 
family. Among seven distinct genotypes, geno-
type 1 is the most frequent in the United States 
and in Western Europe (Lauer and Walker, 2001). 
30% of infected individuals spontaneously clear 
the virus, whereas the others develop chronic 
infection. Morbidity associated with chronic hep-
atitis C mainly results from the development of 
liver fibrosis and cirrhosis, with complications 
such as hepatocellular carcinoma and liver fail-
ure. Treatment of chronic hepatitis C with pegy-
lated IFN- and ribavirin (PEG-IFN-/RBV) 
results in a sustained virological response (SVR) 
in 50% of patients infected with genotype 
1/4, and in 70–90% of those infected with gen-
otype 2/3 (Zeuzem et al., 2009). Although new 
antiviral agents such as telaprevir (Zeuzem 
et al., 2011) and boceprevir (Bacon et al., 2011; 
Poordad et al., 2011) improve cure rates, treat-
ment remains long, burdened with adverse effects, 
costly, with limited availability to many areas, 
and may lead to the emergence of resistance.
Recent genome-wide association studies 
(GWAS) showed that single nucleotide polymor-
phisms (SNPs) nearby IL28B (mainly rs12979860) 
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Approximately 3% of the world population is chronically infected with the hepatitis C virus 
(HCV), with potential development of cirrhosis and hepatocellular carcinoma. Despite the 
availability of new antiviral agents, treatment remains suboptimal. Genome-wide association 
studies (GWAS) identified rs12979860, a polymorphism nearby IL28B, as an important predic-
tor of HCV clearance. We report the identification of a novel TT/-G polymorphism in the CpG 
region upstream of IL28B, which is a better predictor of HCV clearance than rs12979860. By 
using peripheral blood mononuclear cells (PBMCs) from individuals carrying different allelic 
combinations of the TT/-G and rs12979860 polymorphisms, we show that induction of IL28B 
and IFN-–inducible protein 10 (IP-10) mRNA relies on TT/-G, but not rs12979860, making 
TT/-G the only functional variant identified so far. This novel step in understanding the 
genetic regulation of IL28B may have important implications for clinical practice, as the use 
of TT/G genotyping instead of rs12979860 would improve patient management.
© 2013 Bibert et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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rs12979860 (0.46, 95% CI 0.35–0.62, P = 1.527). TT/-G 
still provided the strongest and most significant association 
in a multivariate model, after adjustment for age, sex, HCV 
RNA level, fibrosis stage, and viral genotype (OR = 0.27, 
95% Cl 0.17–0.45, P = 2.707), compared with rs12979860 
(OR = 0.37, 95% CI 0.23–0.59, P = 2.475). When both poly-
morphisms were included in the same model, the mutant -G 
allele of TT/-G was still associated with reduced clearance, 
whereas the mutant T allele of rs12979860 was associated 
with increased clearance (OR>1, Table 2). TT/-G had a better 
ability than rs12979860 to discriminate SVR rates (P = 0.04, 
Fig. 1 A). The SVR proportion was 0.80, 0.55, and 0.41 for 
patients carrying the TT/TT, TT/-G, and -G/-G genotypes, 
compared with 0.77, 0.56, and 0.45 for those carrying 
rs12979860 CC, CT, and TT genotypes (P = 0.02, Fig. 1 B). 
Altogether, this confirms that TT/-G is a better marker for 
HCV clearance than rs12979860 and that the mutant -G allele, 
but not the rs12979860 mutant T allele, is associated with re-
duced clearance. The rs12979860 mutant T allele likely repre-
sents a proxy for the effect of the mutant -G allele.
Similar observations were found after stratification by viral 
genotypes (Tables 1 and 2). In patients infected with HCV 
are strongly associated with spontaneous (Rauch et al., 2010) 
and treatment-induced clearance of HCV infection (Ge et al., 
2009; Suppiah et al., 2009; Tanaka et al., 2009; Rauch et al., 
2010). IL28B encodes type III IFN-3, a cytokine which has 
antiviral properties both in vitro and in vivo (Kotenko et al., 
2003; Sheppard et al., 2003; Meager et al., 2005; Robek 
et al., 2005; Ank et al., 2006; Hou et al., 2009). Numerous 
investigators confirmed the importance of IL28B SNPs in the 
natural course and treatment of HCV infection (Mangia et al., 
2010; Rallón et al., 2010; McCarthy et al., 2010; Lange and 
Zeuzem, 2011).
It remains unknown whether rs12979860 exerts biolog-
ical effects or whether it is in linkage disequilibrium (LD) with 
other functional polymorphisms. The expression of IL28B 
was reported to be lower in whole blood or PBMCs from in-
dividuals carrying the mutant alleles than those carrying the 
WT alleles (Suppiah et al., 2009; Tanaka et al., 2009), but these 
observations were not unequivocally confirmed in liver biopsies 
from patients with chronic hepatitis C (Honda et al., 2010; 
Urban et al., 2010; Dill et al., 2011). The functional effect was 
proposed to result from rs8103142, a nonsynonymous SNP in 
LD with rs12979860, which induces a K-to-R substitution at 
amino acid position 70 of IL28B (Ge et al., 2009). However, 
this SNP was not among the most significantly associated 
with clearance in GWAS. Furthermore, K70 and R70 protein 
variants did not induce different levels of IFN-stimulated 
gene (ISG) expression or different inhibition of HCV replica-
tion in Huh-7.5 cells (Urban et al., 2010). Other investigators 
performed gene mapping but failed to detect new SNPs with 
a stronger genetic effect (di Iulio et al., 2011) or with a clear 
functional mechanism.
RESULTS AND DISCUSSION
By sequencing the putative regulatory region upstream of 
IL28B, we identified a T deletion (previously described as 
rs67272382 NT_011109.16:g.12007372delT) adjacent to 
a T-to-G substitution (previously described as rs74597329 NT_
011109.16:g.12007373T>G), located at position 39739154 
and 39739155 in chromosome 19 (Genome Build 37.1). The 
presence of the TT/-G substitution, as well as the previously 
known rs12979860, was explored in a cohort of 540 Caucasian 
patients with chronic HCV infection and in 93 patients with 
spontaneous HCV clearance (Table S1). The rs12979860 and 
TT/-G polymorphisms were in strong LD (R2 = 0.91) and 
both had a minor allele frequency of 0.38. Despite such strong 
correlation, individuals who were discordant at both SNPs 
allowed us to explore which of the two SNPs is most strongly 
associated with the outcome and therefore more likely to be 
the functional variant.
We assessed whether IL28B polymorphisms were asso-
ciated with response to PEG-IFN-/RBV therapy among 
chronically infected patients. When considering all viral geno-
types together, both polymorphisms were associated with re-
sponse to treatment (Fig. 1, Table 1, and Table S2). The 
strongest and most significant association was found for TT/-G 
(OR = 0.38, 95% CI 0.28–0.51, P = 2.5110), compared with 
Figure 1. TT/-G is a better predictor of response to treatment 
than rs12979860. (A) Association of the mutant -G allele of TT/-G and 
the mutant T allele of rs12979860 with HCV clearance. * , P = 0.04. Error 
bars represent 95% confidence level. (B) TT/-G versus rs12979860 in SVR 
to treatment in chronically HCV-infected patients. **, P = 0.02. Analyses 
were performed in 540 Caucasian patients from the Swiss Hepatitis C 
Cohort Study. Numbers of patients in each group are described in Table 1. 
All genotypes were validated by an independent laboratory as described in 
the materials and methods. Odds ratios are for an additive model, ac-
counting for the effect of one or two copies of the mutant allele. Multi-
variate models are adjusted for age and sex, HCV RNA level, fibrosis stage, 
and viral genotype. P-values were calculated using the integrated dis-
crimination improvement (IDI) test.
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expression in PBMCs from individuals carrying different al-
lelic combinations of rs12979860 and TT/-G that were stim-
ulated with the dsRNA analogue poly(I:C) (Fig. 2, A and C). 
Among individuals WT for rs12979860, PBMCs from those 
carrying one or two copies of the mutant allele -G of TT/-G 
had lower expression of IL28B mRNA compared with those 
from TT/-G WT individuals (P < 0.001). In contrast, among 
individuals WT for TT/-G, those carrying one or two copies 
of the mutant allele T of rs12979860 had similar expression 
of IL28B mRNA than those WT for rs12979860. Finally, 
among individuals carrying one or two copies of the mutant 
allele T of rs12979860, those carrying one or two copies of 
the mutant allele -G of TT/-G had lower expression of IL28B 
mRNA compared with those from TT/-G WT individuals 
(P = 0.007). The pattern of IL28B expression after stimulation 
genotype 1/4, the strongest and most significant association was 
also found for TT/-G either in the univariate (OR = 0.25, 
95% CI 0.16–0.40, P = 4.619 vs. OR = 0.31, 95% CI 0.20–
0.49, P = 2.247 for rs12979860) or in the multivariate models 
(OR = 0.16, 95% CI 0.08–0.33, P = 2.757 vs. OR = 0.22, 
95% CI 0.11–0.41, P = 3.466 for rs12979860). In patients 
infected with HCV genotype 2/3, TT/-G was the only SNP 
associated with response to treatment, but only in a recessive 
model (OR = 0.36, 95% CI 0.15–0.86, P = 2.132). Finally, 
TT/-G was also a better marker of spontaneous clearance 
(Tables 1 and 2, P = 8.689), compared with rs12979860 
(P = 1.668).
Because TT/-G is a better marker of HCV clearance, we 
speculated that it might correlate with IL28B mRNA ex-
pression. To address this issue, we measured IL28B mRNA 
Table 1. Association of IL28B polymorphisms with HCV clearance in chronic hepatitis C
Response to treatment Genotype T NR SVR Prop. SVRb Univariate models Multivariate modelsd
OR(95% CI) P OR (95% CI) P
All viral genotypesa (n = 540)
TT/-G TT/TT 37 152 0.80
TT/-G 131 161 0.55
-G/-G 35 24 0.41 0.38 (0.28–0.51) 2.5110 0.27 (0.17–0.45) 2.707
rs12979860 CC 43 146 0.77
CT 126 163 0.56
TT 34 28 0.45 0.46 (0.35–0.62) 1.527 0.37 (0.23–0.59) 2.475
Viral genotype 1 and 4a (n = 288)
TT/-G TT/TT 82 22 60 0.73
TT/-G 174 112 62 0.36
-G/-G 32 26 6 0.19 0.25 (0.16–0.40) 4.619 0.16 (0.08–0.33) 2.757
rs12979860 CC 80 24 56 0.70
CT 173 109 64 0.37
TT 35 27 8 0.23 0.31 (0.20–0.49) 2.247 0.22 (0.11–0.41) 3.466
Viral genotype 2 and 3c (n = 252)
TT/-G TT/TT 15 92 0.86
TT/-G 19 99 0.84
-G/-G 9 18 0.67 0.36 (0.15–0.86) 2.132 1.33 (0.22–7.94) 7.571
rs12979860 CC 19 90 0.83
CT 17 99 0.85
TT 7 20 0.74 0.54 (0.21–1.38) 2.011 1.48 (0.26–8.53) 6.591
Spontaneous clearance (n = 633)a
TT/-G TT/TT 189 63
TT/-G 292 29
-G/-G 59 1 0.28 (0.18–0.43) 8.689 0.30 (0.19–0.47) 1.547
rs12979860 CC 189 62
CT 289 30
TT 62 1 0.29 (0.19–0.45) 1.668 0.31 (0.20–0.49) 3.647
CRI, chronic infection; SC, spontaneous clearance; NR, nonresponse to treatment; OR, odds ratio; CI, confidence interval; Prop, proportion.
aOdd ratios and p-values are for an additive model, accounting for increased effect of one or two copies of the mutant allele.
bData indicate the proportion of patients with SVR for indicated host and viral genotypes.
cOdd ratios and p-values are for a recessive model, comparing the presence of two copies versus zero or one copies of the mutant allele.
dMultivariate models are adjusted for age and sex (spontaneous clearance), as well as HCV RNA level, fibrosis stage, and, whenever appropriate, viral genotype (response to 
treatment). Multivariate models include a smaller number of patients, due to missing covariates in some patients (n = 360 for all genotypes, n = 195 for genotypes 1 and 4, 
and n = 165 for genotypes 2 and 3). However, the results of univariate analyses restricted to the subset of individuals with all covariates were concordant with those of the 
whole group.
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those carrying the mutant allele of rs12979860 (Fig. 2 B), in-
dicating that Il28B expression could be a determinant for the 
induction of some ISGs. These observations suggest a strong 
link between the mutant -G allele of TT/-G, reduced expres-
sion of IL28B, lower induction of ISGs, and HCV treatment 
failure. However, the mechanisms by which IL28B TT/-G 
genotypes are related to ISG induction and clinical pheno-
types remain to be elucidated. As a control, TNF mRNA 
expression after LPS stimulation was not influenced by both 
polymorphisms (Fig. 2 C).
Genetic polymorphisms can influence gene function 
through different mechanisms. For instance, they can disrupt 
or create DNA regulatory elements affecting gene expression. 
In addition, SNPs can influence the ability of DNA sequences 
to undergo methylation, thereby influencing gene expression. 
Both rs12979860 and TT/-G are located within a CpG island 
which has been identified on the UCSC human genome 
draft by the Miklem and Hillier method. As assessed by bisul-
fite sequencing, TT/-G polymorphism was found to promote 
the methylation of a cytosine residue which is unmethylated 
in WT DNA sequences (Fig. 3). Further studies are needed to 
determine the relationship between TT/-G and surrounding 
CpG methylation and IL28B and/or ISG expression.
Prokunina-Olsson et al. (2013) showed that TT/-G intro-
duces a frame shift in the DNA sequence, which transiently 
induces mRNA expression of an IFN analogue (IFNL4) in 
human hepatocytes stimulated with poly(I:C). Only patients 
carrying the mutant allele -G express IFNL4. The authors 
suggest that this protein could be a direct marker of HCV 
treatment failure and a new target for therapeutic interven-
tion, raising major interest in the medical community. Never-
theless, issues regarding the molecular functions of IFNL4 
remain to be clarified, such as the inability of recombinant 
IFNL4 to directly induce the Jak–STAT pathway in HepG2 
was similar among patients with cured hepatitis C (SVR) and 
those with chronic infection (nonresponse) according to 
TT/-G, suggesting that the viremic state does not significantly 
influence acute response to stimulation in vitro (Fig. 2 C). 
Altogether, these data demonstrate that IL28B mRNA ex-
pression is driven by the presence of one or two mutant al-
leles of TT/-G but not by rs12979860. Because IL28B has a 
strong homology with IL28A due to ancestral gene duplica-
tion events, we sequenced previously cloned amplicons to 
unambiguously confirm that they were part of IL28B but not 
IL28A (unpublished data).
Although the number of individuals carrying discrepant 
genotypes was low, the reduction in IL28B mRNA expres-
sion among samples from individuals carrying the mutant 
TT/-G allele was strongly significant. Recently, Prokunina-
Olsson et al. (2013) also identified TT/-G as a better predic-
tor of response to treatment than rs12979860 among African 
Americans, whereas it did not improve this prediction among 
Caucasians. This can be explained by the lower level of LD 
between the two polymorphisms among African Americans 
(R2 = 0.71) compared with Caucasian (R2 = 0.92). Thus, the 
high proportion of rs12979860 and TT/-G discrepant indi-
viduals in the African American population would allow fur-
ther validation of the functional role of TT/-G on IL28B 
mRNA expression.
Infection with HCV activates the endogenous IFN sys-
tem, which leads to the induction of ISGs and contributes to 
viral clearance. Pretreatment plasmatic levels of ISGs, such as 
IFN-–inducible protein 10 (IP-10), are predictors of HCV 
clearance. Because the induction of IP-10 is thought to rely 
on both type I and type III IFNs, we analyzed IP-10 mRNA 
expression in PBMCs stimulated with poly(I:C) for 8 h (Fig. 2, 
B and C). As for IL28B, IP-10 expression was lower among 
individuals carrying the mutant allele of TT/-G but not in 
Table 2. Independent contribution of rs12979860 and TT/-G to HCV clearance
Response to treatment Polymorphisms included in the same model
OR (95% CI) P
All viral genotypes; n = 540
Polymorphisms by pairs
TT/-G 0.12 (0.03–0.40) 5.944
rs12979860 3.41 (1.01–11.4)a 4.772
Viral genotypes 1 and 4, n = 288
Polymorphisms by pairs
TT/-G 0.16 (0.05–0.55) 3.603
rs12979860 1.61 (0.48–5.40)a 4.441
Spontaneous clearanceb
Polymorphisms by pairs
TT/-G 0.42 (0.14–1.30) 1.311
rs12979860 0.66 (0.22–1.99) 4.591
Both TT/-G and rs12978960 were introduced in the same logistic regression model. OR, odds ratio; CI, confidence interval. OR represent the additive effect of the mutant allele 
(-G for TT/-G and T for rs12979860).
aWhen TT/-G was entered into the model, the direction of the association of the T allele of rs12979860 was reversed (OR > 1).
b93 individuals with spontaneous HCV clearance were compared to 540 patients with chronic infection
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Figure 2. Expression of IL28B and IP-10 mRNA relies on TT/-G but not rs12979860 polymorphism. PBMCs from healthy and HCV-infected indi-
viduals were stimulated with poly(I:C) for 4 h (black) and 8 h (dark gray). The mRNA expression of IL28B and IP-10 was measured by RT-PCR. Results grouped 
according to different allelic combinations of the mutant T allele of rs12979860 and the mutant -G allele of TT/-G are shown in A (IL28B) and B (IP-10). Indi-
vidual results are shown in C. As a control, TNF expression was measured after stimulation with LPS (C, bottom). AU, arbitrary units; mut, mutant allele;  
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age, sex, HCV risk factors, HCV genotypes, alcohol consumption, markers of 
chronic infection with the hepatitis B virus and HIV, HCV viral load, liver 
biopsy data, and HCV treatment were extracted from clinical databases. SVR 
was defined as an undetectable HCV RNA in serum more than 24 wk after 
treatment termination. Severe fibrosis was considered in patients with a 
METAVIR score F3 or higher.
SNP genotyping. TT/-G and rs12979860 were extracted from a GWAS-
generated dataset (Rauch et al., 2010) or genotyped by TaqMan (Applied 
Biosystems), using the ABI 7500 Fast real time thermocycler, according to 
manufacturer’s protocols. For TT/-G and rs12979860, TT and C were de-
fined as WT and -G and T as mutant alleles, respectively. TaqMan probes and 
primers were designed and synthesized using Applied Biosystems software 
(Table S3). Automated allele calling was performed using SDS software 
(Applied Biosystems). For quality control, all samples were also genotyped in 
an independent laboratory (KBioscience, Unit 7, Maple Park, Hoddesdon, 
Herts, UK) using KASP SNP genotyping system, a competitive allele-
specific PCR incorporating a FRET quencher cassette. Patients with at least 
one missing genotype and/or discordant results regarding one polymorphism 
were excluded from the analyses.
Statistical analysis. Statistical analyses were performed using Stata (ver-
sion 11.1, StataCorp LP). LD and Hardy-Weinberg equilibrium test were 
assessed using the programs pwld and genhw, respectively, both imple-
mented in Stata. Strong LD was defined as an R2 > 0.7. The association 
of IL28B polymorphisms with response to treatment and spontaneous 
clearance was performed by univariate and multivariate logistic regres-
sion. Age, duration of infection, and body mass index (BMI) were treated 
as continuous variables. Multiple logistic regression models were adjusted 
for age, sex, HCV RNA level, fibrosis stage, and, whenever appropriate, 
viral genotype. For IL28B SNPs, comparisons were made using an addi-
tive model (considering a similar effect for each additional copy of the 
minor allele), a neutral model (comparing separately patients with hetero-
zygous and homozygous mutant genotypes to patients with WT geno-
types), and, when appropriate, a recessive model (comparing patients with 
homozygous mutant genotypes to the others). Discrimination ability be-
tween two different logistic regression models was compared using the 
integrated discrimination improvement test (IDI) implemented in Stata 
(Pencina et al., 2008).
PBMCs isolation and RT-PCR analysis. PBMCs were prepared from 
1.6 mg/ml of fresh EDTA blood from nine patients and six healthy donors 
with written consent and approval of Ethics committee. In brief, whole 
blood diluted in PBS was overlaid above Ficoll-Paque Plus (GE Healthcare) 
and mononuclear cells extracted by gradient density centrifugation. Viability, 
determined by trypan blue exclusion, was >90%. PBMCs were stimulated 
with 50 µg/ml poly(I:C) and 0.1 µg/ml LPS for 4 or 8 h. Total RNA was 
isolated from PBMCs using an RNeasy Mini kit and the automated QIAcube 
(QIAGEN). 250 ng of total RNA was reverse transcribed using the Quanti-
Tect Reverse Transcription kit (QIAGEN). The relative levels of IL28B, 
IP-10, and TNF transcripts were determined by RT-PCR, with a 7500 Fast 
real-time PCR system (Applied Biosystems), using the Power SYBR green 
PCR master mix (Applied Biosystems) with primers described in Table S3. 
Primers were designed using the Primer 3 software and validated by BLAST 
analysis. The relative levels of mRNA expression to HPRT were determined 
by the 2(Ct) method and expressed in arbitrary units. HPRT expression 
was not influenced by cell stimulation. The PCR products were run on a 2% 
agarose gel, purified (QIAquick Gel extraction kit; QIAGEN), cloned into a 
pGEM-T Easy vector (Promega), and sequenced on an ABI3130XL Se-
quencer (Applied Biosystems).
cells, unless by transfection of an IFNL4 construct. Further-
more, the low secretion level of IFNL4 together with the lack 
of demonstration of its effective binding to the IFNL recep-
tor and/or another specific receptor raises questions about its 
physiological function.
Using a large European cohort, we identified a new TT/-G 
polymorphism nearby IL28B that influences both IL28B and 
IP-10 mRNA expression and improves HCV clearance pre-
diction in patients infected with HCV viral genotype 1/4 or 
2/3. Because IL28B has antiviral properties, reduced IL28B 
expression may impair individual ability to clear HCV by it-
self. Whether this phenomenon is further influenced by an-
other protein remains to be demonstrated. TT/-G genotyping 
may have an important impact on the management of both 
African American and Caucasian patients with chronic hepa-
titis C. Altogether, the identification of this TT/-G functional 
variant provides a new step in understanding the role of IL28B 
polymorphisms in the prediction of the response to chronic 
hepatitis C treatment.
MATERIALS AND METHODS
Study patients. Patients were included from the Swiss Hepatitis C Cohort 
Study (SCCS), a multicenter study of >3,700 HCV-infected patients 
enrolled at eight major Swiss hospitals and their local affiliated centers since 
2001 (Prasad et al., 2007; Bochud et al., 2009). Caucasian patients enrolled in 
the SCCS before August 1, 2010, with available DNA and written consent 
for genetic studies were selected. The study included patients with spontane-
ous HCV clearance (defined as presence of anti-HCV but undetectable 
HCV RNA without previous antiviral treatment) and those who had chronic 
infection with HCV genotypes 1, 2, 3, or 4 and were assessable for response 
to therapy with pegylated-IFN- and ribavirin, i.e., who received >80% of 
the recommended dose of each drug. Demographic characteristics including 
NA, not assessed; NR, nonresponse to treatment. For each individual, stimulation was performed in triplicate. P-values are calculated by linear regression.  
* , P < 0.001; **, P = 0.007; +, P < 0.001; ++, P = 0.006. N stands for the number of individuals. Error bars represent standard error. #, unstimulated cells.
 
Figure 3. The TT/-G creates a methylation site in the CpG region. The 
TT/-G substitution is associated with the methylation of the adjacent cyto-
sine residue (indicated by arrow). As opposed to methylated cytosine resi-
dues (indicated by asterisks), unmethylated cytosine residues, C, are replaced 
by thymine, T, after bisulfite treatment and subsequent PCR amplification.
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